Hematopoietic stem cell transplant as a platform for tumor immunotherapy

Research output: Contribution to journalReview articlepeer-review


Blood or marrow transplantation (BMT) has been utilized as a cancer therapy with varying levels of success. While it has been an important option for many hematological malignancies, it has met with less success in solid tumors. More recently, new combinations of therapies with BMT have been developed to enhance the efficacy of this therapy and to expand the number of target tumors. This review highlights current uses of BMT, rationales for experimental approaches using BMT alone or as a part of a combination therapy, and reviews some of the novel therapies that have been developed in tumor immunotherapy with BMT, in addition to the implications for translation.

Original languageEnglish (US)
Pages (from-to)48-53
Number of pages6
JournalCurrent Opinion in Molecular Therapeutics
Issue number1
StatePublished - Feb 1 2004


  • Blood or marrow transplant
  • Donor lymphocyte infusion
  • Gene therapy
  • Immunotherapy
  • Tumor vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)


Dive into the research topics of 'Hematopoietic stem cell transplant as a platform for tumor immunotherapy'. Together they form a unique fingerprint.

Cite this